Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
This study suggests that Lp(a)-lowering by 50 mg/dL (105 nmol/L) short-term (ie, 5 years) may reduce CVD by 20% in a secondary prevention setting.High Lp(a) (Lipoprotein[a]) is associated with high risk of incident cardiovascular disease (CVD) in observational studies of individuals without CVD at baseline<sup>1, 2</sup>, that is, in a primary prevention setting.
|
31578080 |
2020 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Age (OR: 1.07; 95% CI: 1.03, 1.10), male sex (OR: 1.95; 95% CI: 1.68, 2.23), hypertension (OR: 2.11; 95% CI: 1.64, 2.58), diabetes (OR: 1.95; 95% CI: 1.33, 2.57), body mass index (OR: 1.04; 95% CI: 1.03, 1.05), smoking (OR: 1.71; 95% CI: 1.30, 2.12), elevated lipoprotein(a) (OR: 1.90; 95% CI: 1.10, 2.71), low high-density lipoprotein cholesterol (OR: 1.39; 95% CI: 1.24, 1.53), and a family history of CVD (OR: 1.83, 95% CI: 1.58, 2.07) were found to be significant CVD risk factors in FH.
|
30527766 |
2020 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Patients with metabolic syndrome (MetS) are at high risk of developing cardiovascular disease (CVD) and lipoprotein(a) (Lp(a)) is an independent risk factor for CVD.
|
31625055 |
2020 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The association between lipoprotein(a) [Lp(a)] levels and the risk of cardiovascular disease is of great interest but still controversial.
|
31740238 |
2020 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Lipoprotein (a) and 10-year Cardiovascular Disease Incidence in Apparently Healthy Individuals: A Sex-based Sensitivity Analysis from ATTICA Cohort Study.
|
31185726 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Several lipoprotein(a)-lowering therapies are currently being developed with the long-term goal of reducing cardiovascular disease and mortality; however, the relationship between lipoprotein(a) and mortality is unclear.
|
30608559 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Lipoprotein(a) as a key target in combined therapeutic approaches for cardiovascular disease.
|
31530423 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Elevated low-density lipoprotein cholesterol and/or lipoprotein(a) are established risk factors for cardiovascular disease (CVD).
|
30799420 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Those with evidence of CAD were significantly more likely to be male, inactive, diabetic and with a family history of CVD than participants without CAD.About 20% of patients had lipoprotein(a) (Lp(a)) concentrations above 106.9 nmol/L (fifth quintile).
|
31481563 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
It is well-known that Lp(a) levels have an impact on increased risk of CVD which is affected by LPA gene.
|
31113255 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
The causal relationship of lipoprotein(a) with cardiovascular disease has been established.
|
31577620 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Malondialdehyde, lipoprotein-a, lipoprotein ratios, comprehensive lipid tetrad index and atherogenic index as surrogate markers for cardiovascular disease in patients with psoriasis: a case-control study.
|
30830310 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Lipoprotein (a) [Lp(a)] is an established causal risk factor for cardiovascular disease (CVD), independently of low-density lipoproteins (LDL) and other risk factors.
|
31493849 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease.
|
30675027 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Lipoprotein(a) [Lp(a)] has been considered as a causal risk factor for cardiovascular disease (CVD) in the general population and levels vary in different ethnicities.
|
31683090 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Elevated Lipoprotein(a) (Lp[a]) is a well-known risk factor for cardiovascular disease.
|
31023762 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Cardiovascular Diseases
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The greatest frequency of cardiovascular disease (CVD; 69%) was observed in DM[-]EOCHD[+] patients, whose lipoprotein(a) and insulinemia were also highest (81 nmol/L and 140 pmol/L, respectively).
|
30105804 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Recently, lipoprotein(a) has emerged as an important cardiovascular risk factor and lipoprotein apheresis has been used to decrease lipoprotein(a) concentrations in patients with marked elevations and cardiovascular disease.
|
31041550 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Elevated serum lipoprotein(a) [Lp(a)] levels are associated with increased cardiovascular disease risk.
|
31220285 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members.
|
30150142 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Clinical trials are under way to lower the lipoprotein (a) (Lp(a)) and its associated oxidized phospholipids, which will provide clinical evidence that targeting inflammation caused by oxidized lipids is a viable approach for CVD.
|
30946962 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
In patients who cannot be treated adequately by drugs it is possible to reduce increased LDL-C and/or lipoprotein(a) (Lp(a)) values by the use of lipoprotein apheresis (LA) with the potential to decrease severe CVD events in the range of 70%->80%.
|
31818446 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Background Elevated lipoprotein(a) (Lp(a)), a low-density lipoprotein-like particle bound to the polymorphic apolipoprotein(a) (apo(a)), may be causal for cardiovascular disease.
|
30897995 |
2019 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Homocysteine and education but not lipoprotein (a) predict estimated 10-year risk of cardiovascular disease in blood donors: a community based cross-sectional study.
|
31349819 |
2019 |